Sotac Pharmaceuticals Ltd
Fundamental Score
Sotac Pharmaceuticals Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SOTAC across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (15.71%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (15.06%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Attractive Valuation (P/E: 17.88 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (28.27%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Consistent Growth Track Record (27.65% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (82.29% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (149.51% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Balanced Promoter Holding (72.85%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
2 factors identified
Revenue Contraction (-29.63%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Sotac Pharmaceuticals Ltd
About SOTAC
Company Details
SOTAC Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Sotac Pharmaceuticals Ltd (SOTAC)?
As of 30 Jan 2026, 01:39 pm IST, Sotac Pharmaceuticals Ltd (SOTAC) is currently trading at ₹118.30. The stock has a market capitalization of ₹153.04 (Cr).
Is SOTAC share price Overvalued or Undervalued?
SOTAC is currently trading at a P/E ratio of 17.88x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Sotac Pharmaceuticals Ltd share price?
Key factors influencing SOTAC's price include its quarterly earnings growth (Sales Growth: -29.63%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sotac Pharmaceuticals Ltd a good stock for long-term investment?
Sotac Pharmaceuticals Ltd shows a 5-year Profit Growth of 149.51% and an ROE of 15.71%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.69 before investing.
How does Sotac Pharmaceuticals Ltd compare with its industry peers?
Sotac Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare SOTAC's P/E of 17.88x and ROE of 15.71% against the industry averages to determine its competitive standing.
What is the P/E ratio of SOTAC and what does it mean?
SOTAC has a P/E ratio of 17.88x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹18 for every ₹1 of annual earnings.
How is SOTAC performing according to Bull Run's analysis?
SOTAC has a Bull Run fundamental score of 57.5/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does SOTAC belong to?
SOTAC operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sotac Pharmaceuticals Ltd.
What is Return on Equity (ROE) and why is it important for SOTAC?
SOTAC has an ROE of 15.71%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Sotac Pharmaceuticals Ltd generates profits from shareholders' equity.
How is SOTAC's debt-to-equity ratio and what does it indicate?
SOTAC has a debt-to-equity ratio of 0.69, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is SOTAC's dividend yield and is it a good dividend stock?
SOTAC offers a dividend yield of 0.07%, which means you receive ₹0.07 annual dividend for every ₹100 invested.
How has SOTAC grown over the past 5 years?
SOTAC has achieved 5-year growth rates of: Sales Growth 27.65%, Profit Growth 149.51%, and EPS Growth 82.29%.
What is the promoter holding in SOTAC and why does it matter?
Promoters hold 72.85% of SOTAC shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is SOTAC's market capitalization category?
SOTAC has a market capitalization of ₹153 crores, placing it in the Small-cap category.
How volatile is SOTAC stock?
SOTAC has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for SOTAC?
SOTAC has a 52-week high of ₹N/A and low of ₹N/A.
What is SOTAC's operating profit margin trend?
SOTAC has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is SOTAC's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -29.63% and YoY Profit Growth of 28.27%.
What is the institutional holding pattern in SOTAC?
SOTAC has FII holding of 16.14% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.